Bristol-Myers acquires Cardioxyl, Shire buys Dyax

Bristol-Myers Squibb Co has bought privately-held drug developer Cardioxyl Pharmaceuticals Inc for $2.07 billion to gain access to a heart-failure treatment. Another drugmaker, Shire Plc, will buy Dyax Corp for $5.9 billion to gain access to the latter’s experimental treatment for an inflammatory disease that can block breathing.